Lumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All Endpoints
07 Noviembre 2023 - 5:24PM
Noticias Dow Jones
By Ben Glickman
Shares of Lumos Pharma soared on Tuesday after the company said
its hormone deficiency treatment met all of its endpoints in a
trial.
The stock rose 117% to $7.91 at 5:35 pm. ET in post-market
trading, which followed a 4% rise at Tuesday's close. Shares are up
0.8% this year.
The Austin, Texas-based pharmaceutical company said its Phase 2
trial of LUM-201 in pediatric growth hormone deficiency patients
showed that its treatment could be a viable alternative to
injectable hormone deficiency therapies.
The company's Phase 2 dose-finding trial and Phase 2
pharmacokinetic/pharmacodynamic trial met all of their primary and
secondary endpoints.
Lumos said a 1.6 milligram per kilogram dose of LUM-201 led to a
growth rate comparable to that of the moderate PGHD population.
The company will meet with the Food and Drug Administration in
the first quarter of 2024 and finalize plans for a Phase 3
trial.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 07, 2023 18:09 ET (23:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Lumos Pharma (NASDAQ:LUMO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lumos Pharma (NASDAQ:LUMO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
